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Abstract 
Background 
Trials of lowering blood pressure in patients with acute ischaemic stroke not undergoing 
thrombolysis have not demonstrated improved outcomes with intervention. Rather than absolute 
levels, it may be that blood pressure variability is important. However, there are no prospective 




The primary aim of this trial was to determine the feasibility of recruitment to a randomised trial 
investigating the effect of different antihypertensive medications on blood pressure variability. 
 
Methods 
CAARBS was a multi-centre, open-label, randomised parallel group controlled feasibility trial. Adults 
with a first mild-moderate ischaemic stroke or transient ischaemic attack, requiring antihypertensive 
therapy for secondary prevention, were randomised to a calcium channel blocker or angiotensin-
converting enzyme inhibitor/angiotensin receptor blocker. Blood pressure and variability were 
measured at baseline, three weeks, and three months. Compliance with measurements and 
treatment was monitored. 
 
Results 
Fourteen patients were recruited to the trial (0.6% of those screened), nine of whom completed 











intervention was good, as were measurement completion rates (88.9% or higher in all cases except 
ambulatory measurements). No major adverse events were recorded. 
 
Conclusions 
Recruitment to the trial was difficult due to patient ineligibility, suggesting that the current protocol 
is unlikely to be successful if scaled for a definitive trial. However, the intervention was safe, and 
compliance was good, suggesting a future trial with modified eligibility criteria could be successful. 
 
Trial registration: ISRCTN10853487 
Keywords: blood pressure variability, hypertension, stroke. 
 
Introduction 
Following an acute ischaemic stroke, blood pressure (BP) levels are frequently raised, even in the 
absence of known prior hypertension.1 Reasons for increased BP are multifactorial, but may relate to 
the maintenance of blood flow to the ischaemic penumbra in the context of dysfunctional cerebral 
autoregulation.2 Data from major stroke trials indicate that raised BP in the acute period is 
associated with a poor prognosis,3 yet trials investigating the treatment of raised BP in these 
patients have not shown any benefit from intervention,1 even if administered within 1-2 hours of 
symptom onset.4 Indeed, one trial has suggested intervention may be harmful.5 Furthermore, low BP 
is probably also detrimental, with data demonstrating a “U” shaped relationship between BP in the 
acute period, and both short- and long-term mortality.6 Consequently, the management of raised BP 
in acute stroke remains uncertain, with guidelines suggesting that it is unlikely to be beneficial to 
start or continue treatment in the first few days unless there are adverse features of accelerated 
hypertension or the patient has had thrombolytic therapy.7  
 
An alternative consideration is that it may be BP variability (BPV), not absolute BP level, which is 
important in the acute phase of ischaemic stroke,8 as evidence indicates that BPV is an independent 
cardiovascular risk factor.9 BP fluctuations may damage the vulnerable ischaemic penumbra, with 
dips causing hypoperfusion and infarct expansion, and rises causing oedema and haemorrhagic 
transformation. This may at least partly explain the “U” shaped relationship between BP and stroke 
outcome. Furthermore, research has demonstrated that BPV is increased in acute ischaemic 
stroke,10 is associated with adverse outcomes,11, 12 and is associated with the risk of recurrent 
stroke.13 Whether BPV is a potential target for therapeutic intervention has not been investigated in 











influence BPV.14, 15 Calcium channel blockers (CCB) and thiazide-like diuretics are consistently 
reported to lower BPV, whereas beta blockers increase it as possibly do renin-angiotensin 
inhibitors.14-16 There is a need for prospective randomised trials to investigate whether lowering BPV 
conveys any benefit in terms of morbidity and mortality after ischaemic stroke.  
 
Aims 
The primary aim of this study was to determine the feasibility of recruiting patients with an acute 
ischaemic cerebrovascular event to a randomised trial investigating the effect of different 
antihypertensive medications on BPV. Secondary feasibility aims were assessment of the viability of 
measuring a change in BPV at 90 day follow-up, assessment of compliance with treatment and trial 
measurements, and safety. 
 
Methods 
The Calcium channel (CCB) or Angiotensin converting enzyme inhibitor (ACEI)/Angiotensin receptor 
blocker (ARB) Regime to reduced Blood pressure variability in acute ischaemic Stroke (CAARBS) 
study was a multi-centre, open-label, randomised parallel group controlled feasibility trial. The 
protocol has previously been published.17 In brief, eligible patients were aged ≥18 years with a first-
episode transient ischaemic attack (TIA) or mild/moderate ischaemic stroke (NIHSS <10), presenting 
within 72 hours of symptom onset, and requiring antihypertensive therapy for secondary stroke 
prevention (defined as repeated clinic BP >130/80mmHg). Where symptom onset time was unclear 
it was taken to be the last time the patient was seen well. Patients were excluded if they had a 
known contraindication to the proposed investigational medicinal products, clinically required 
treatment with a specific class of antihypertensive, had a pre-event modified Rankin score (mRS) >3, 
life expectancy <3 months, or atrial fibrillation (AF). Due to higher than expected rates of patient 
ineligibility, the eligibility criteria were substantially amended during the trial, following discussion 
with the Trial Steering Committee. Specifically, the allowed time from symptom onset was increased 
from <72 hours to <7 days. It was hoped this would improve recruitment and further help inform 
protocol design for any subsequent definitive trial.  
 
Patients presenting to inpatient and outpatient stroke services were screened for eligibility. In 
accordance with local protocols, pre-existing antihypertensive therapy was stopped at admission 
and antihypertensive therapy was not commenced until at least 48 hours after symptom onset 
unless clinically indicated. All diagnoses were reviewed by two experienced stroke physicians. 











in a 1:1 ratio using a computer generated protocol in blocks of four, to treatment with either a 
dihydropyridine CCB or an ACEI/ ARB. Intervention groups were defined by antihypertensive class, 
with the choice of medication from the randomly allocated class at the discretion of the treating 
clinician. Ethical approval for the trial was granted by the London – Central Research Ethics 
Committee (REC No. 17/LO/1427).   
 
At baseline, demographic and clinical details were recorded with BP from enhanced clinic 
monitoring, beat-to-beat monitoring, and daytime ambulatory BP monitoring (ABPM), and a 
cognitive battery (Montreal Cognitive Assessment (MoCA), Albert’s line test, and Motor Neuron 
Disease Behavioural Instrument (MiND-B)). Enhanced clinic monitoring was defined as two sets of 
three BP measurements taken using an appropriately sized cuff with the patient seated, after a 
period of five minutes rest, with at least one minute between readings and 10 minutes between 
sets. Measurements were taken using a semi-automated oscillometric BP monitor (Omron 705IT, 
Omron Healthcare UK Ltd., Milton Keynes, UK). Three 10 minute recordings of non-invasive beat-to-
beat BP were taken using the Finapres® MIDI device (Finapres Medical Systems, Enschede, The 
Netherlands) fitted to the middle finger of the unaffected hand with the patient in the supine 
position. The servo adjust mechanism was disabled during recording and re-applied prior to each 10 
minute period. Daytime ABPM was conducted using a Spacelabs 90207 monitor (Spacelabs 
Healthcare Ltd. (UK), Hertford, UK) programmed to measure BP at 20 minute intervals. BPV was 
derived as the standard deviation (SD) and coefficient of variation (CV) using all BP measurements 
from a set. Interim follow-up was completed after 21 ± 7 days to assess treatment compliance with a 
tablet count and a self-rating scale,18 and repeat enhanced clinic and beat-to-beat BP 
measurements. Participants were questioned about treatment side effects and the ACEI/ARB group 
had blood renal function testing as a safety measure, as per routine clinical practice. Final follow-up 
was completed after 90 ± 14 days, at which time treatment compliance assessment, all baseline BP 
measurements, assessment of stroke severity and functional recovery, and the cognitive battery 
were repeated. 
 
The primary outcome measure for the trial was the assessment of rates of recruitment and 
retention, including reasons for exclusion. Secondary feasibility outcomes were (i) change in BPV 
from baseline to follow-up by intervention arm; (ii) rates of treatment compliance and 
discontinuation; (iii) completion rates of BPV measurements; (iv) serious adverse events. Secondary 
exploratory outcomes were (i) difference in mean BP and BPV at day 21 and day 90 by intervention 











intervention arm. Although the primary objective was the assessment of feasibility, a sample size 
calculation was performed to estimate the number of participants required to detect a potential 
difference in BPV between intervention arms. Assuming a mean systolic BPV SD of 14.97mmHg in 
the CCB arm and 16.95mmHg in the ACEI/ARB arm,15 a sample of 150 patients (64 per group 
allowing for a 15% drop-out rate) was estimated to be required to detect an 8mmHg difference in 
systolic BPV with 80% power at the 5% significance level.  
 
Statistical analysis 
Data were analysed using SPSS (version 25.0). Only descriptive analyses were undertaken, in keeping 
with the CONSORT recommendations for reporting feasibility trials.19 The proportion of patients 
screened that were eligible for the trial, the proportion of eligible patients that were recruited, and 
the proportion of participants that completed follow-up were determined from screening and 
management logs. Reasons for ineligibility were assessed. Where known, reasons for eligible 
patients declining to participate and reasons for participants withdrawing from the trial were 
assessed. All exploratory variables were assessed for normality. Normally distributed variables are 
presented as mean (SD) and non-normally distributed variables are presented as median (IQR). For 




Recruitment commenced on 3rd January 2018 and continued until 31st December 2018 (the pre-
specified end date), with all follow-up completed three months post-randomisation. A total of 2321 
patients were screened, 14 (0.6%) of whom were eligible and consented to participate (Figure 1). Of 
those screened, 2264 (98.1%) were ineligible, with 1858 (81.7%) having a single reason for exclusion 
recorded and 463 (18.3%) having multiple reasons recorded. The most common reasons for 
ineligibility were recurrent stroke/TIA (N=496 [21.4%]), non-stroke diagnosis (N=453 [19.5%]), and 
concurrent AF (N=431 [18.5%] Supplementary Table I). Late presentation beyond the 72 hour 
window of eligibility was also a prominent reason for exclusion (N=314 [19.4%]), but became less 
frequent following the substantial amendment to the eligibility criteria (N=46 [6.6%]).  
 
In addition to the excluded patients, 43 (1.9%) met the eligibility criteria but declined to participate. 
These patients were not obliged to provide a reason for their decision, but some stated that they 











appointments (N=3), despite the offer of reimbursement for travel costs. Two patients did not like 
the idea of being randomly assigned to a medical treatment.  
 
Randomised participants were evenly split between the two intervention groups, allowing for the 
small sample size. Baseline characteristics are displayed in Table 1. Two participants were withdrawn 
as “screening failures” as their initial BP was >130/80mmHg, but repeated measurements at the 
baseline consultation were below the threshold value making them ineligible. One participant 
withdrew from the CCB arm of their own choice, one participant was withdrawn from the ACEI/ARB 
arm by the trial team due to concomitant treatment with a CCB commenced by clinicians outside of 
the trial team, and one participant from the ACEI/ARB arm discontinued treatment due to side 
effects. There were no other major side effects reported and no serious adverse events recorded in 














Table 1: Baseline characteristics of randomised participants. Data presented are mean (SD), 
frequency (%), or median (IQR). 
 CCB ACEI/ARB 
N  5 7 
Age (years)  74.8 (4.2) 64.9 (9.1) 
Gender Male 4 (80.0%) 4 (57.1%) 
Ethnicity White-British 4 (80.0%) 6 (85.7%) 
BMI (kg/m2)  28.2 (4.6) 27.1 (5.8) 
Smoking Never smoked 2 (40.0%) 2 (28.6%) 
Ex-smoker 3 (60.0%) 2 (28.6%) 
Current smoker 0 (0.0%) 3 (42.8%) 
Alcohol (units/wk)  5 (0-17) 14 (12-38) 
Diagnosis TIA 3 (60.0%) 3 (42.9%) 
Stroke 2 (40.0%) 4 (57.1%) 
Past medical 
history 
Hypertension 3 (60.0%) 1 (14.3%) 
Diabetes 1 (20.0%) 0 (0.0%) 
Ischaemic heart 
disease 
0 (0.0%) 0 (0.0%) 
Mean enhanced 
clinic BP (mmHg) 
SBP 163.6 (17.3) 152.7 (14.5) 
DBP 81.8 (5.9) 83.1 (6.5) 
SD enhanced clinic 
BP (mmHg) 
SBP 8.4 (5.2) 6.8 (5.3) 
DBP 5.6 (3.0) 6.0 (3.4) 











BP (%) DBP 7.0 (3.9) 7.2 (4.0) 
Mean beat-to-beat 
BP (mmHg) 
SBP 156.6 (5.7) 151.0 (11.9) 
DBP 79.8 (7.1) 82.6 (6.1) 
SD beat-to-beat BP 
(mmHg) 
SBP 9.9 (3.9) 9.2 (5.5) 
DBP 5.2 (2.2) 5.1 (2.4) 
CV beat-to-beat BP 
(%) 
SBP 6.3 (2.5) 6.0 (2.6) 
DBP 6.6 (2.6) 6.3 (3.0) 
CCB denotes calcium channel blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin receptor blocker; BMI, body mass index; TIA, transient ischaemic attack; BP, blood 
pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; SD, standard deviation; CV, 
coefficient of variation. 
 
Completion rates of clinic and beat-to-beat BP measurements were good across all study visits, with 
all completed readings judged to be valid (Table 2). Completion rates of daytime ABPM 
measurements were lower, partly because of a software failure at one trial site, and partly because 
of participant refusal (N=2). Furthermore, only 6/13 (46.2%) daytime ABPM measurements provided 
≥14 readings and were considered valid for analysis. Compliance with trial treatment according to 
the self-rating questionnaire was good, with 8/9 (88.9%) participants who completed the trial 
indicating compliance ≥80%. However, tablet count was unsuccessful as participants often failed to 
bring their medication to follow-up visits, being completed in only 5/18 (27.7%) consultations.  
 
 
 Table 2: Completion rates of blood pressure measurements. 
 Enhanced clinic BP Beat-to-beat BP Daytime ABPM 
Baseline 12/12 (100.0%) 11/12 (91.7%) 7/12 (58.3%) 
21 days 9/10 (90.0%) 9/10 (90.0%) - 
90 days 9/9 (100.0%) 8/9 (88.9%) 6/9 (66.6%) 













Enhanced clinic BP was possibly reduced to a greater degree at 90 days with CCB compared to 
ACEI/ARB (-35/-9mmHg vs. -22/-8mmHg), but clinic BPV reduction was similar (SD -3/-1mmHg vs. -
3/-3mmHg, CV -1/-1% vs. -1/-3% [Supplementary Table II]).  Reductions in beat-to-beat BP and BPV 
were possibly greater with CCB (mean BP -20/-8mmHg vs. -14/-7mmHg, SD -4/-2mmHg vs. -1/-
1mmHg, CV -2/-2% vs. 0/-1%[Supplementary Table III]). There were no apparent differences in 




Recruitment to this trial was difficult owing to high rates of patient ineligibility. Recruitment targets 
were not met and it seems unlikely that it would be feasible to scale up the current protocol to 
attempt a definitive trial. However, despite the proportion of eligible patients recruited being low, 
this is not necessarily unusual for randomised controlled trials.20 Furthermore, retention in this trial 
was reasonable, with 9/14 (64.3%) randomised participants completing three-month follow-up. The 
main reasons for patient ineligibility were having a previous cerebrovascular event, non-stroke 
diagnosis, presenting beyond the window of eligibility, and having concurrent AF. A proportion of 
patients presenting with a stroke mimic must be accepted, but other criteria could potentially be 
altered to improve recruitment. Firstly, although extending the eligibility window did not translate 
into a significant increase in recruitment in this trial, retaining the extension could be helpful. It 
would increase the likelihood of eligibility at the point of presentation to stroke services and it may 
also allow time for patients initially too unwell to participate (e.g. if they are nil by mouth) to recover 
sufficiently for inclusion. Secondly, although increased BPV may persist chronically post-stroke,21 
large gains could be achieved by including patients with a previous stroke . Employing minimisation 
criteria to balance first and recurrent stroke patients in each trial arm, or pre-specified statistical 
techniques, such as planned subgroup analysis of patients with first episode stroke or adjustment for 
previous stroke in statistical testing, could safeguard their inclusion. Thirdly, as most patients require 
multiple agents to achieve BP control,22 it may be necessary to include patients taking 
antihypertensive medications other than the intervention products. Again, techniques such as pre-
specified subgroup analysis or adjustment in statistical testing could control for their inclusion. A 
treatment escalation algorithm would minimise unintentional intervention group crossover during 
follow-up, whilst allowing for treatment intensification. Finally, as beat-to-beat BPV is increased in 
patients with AF compared to control,23 and beta blockers are frequently used as part of a rate 
control treatment strategy for AF,24 it may be difficult to justify including patients with AF. However, 











measurements are taken.25 Therefore, if BPV from clinic or ambulatory monitoring rather than beat-
to-beat measurements was used, it may be possible to include them. Further safeguarding could be 
achieved with specified data validation criteria for patients with AF, such as an acceptable range for 
heart rate variability across BP measurements used to derive BPV. 
 
There are no directly comparable trials to this one and so its novelty should be noted. The major 
strength of the trial is in its feasibility design, with accomplishment of the primary objective and 
analysis allowing for recommendations to be made which could improve recruitment in a future 
trial. The trial also met its secondary feasibility objectives, although these findings must be 
interpreted in the context of the small sample size, demonstrating good compliance with the 
intervention and trial measurements (ABPM measurements being largely limited by a technical 
issue), and raising no safety concerns. Furthermore, it was demonstrated that it is possible to 
measure a change in BPV over a three-month follow-up period in this patient group, indicating that if 
sufficient numbers of participants could be recruited, it should be possible to detect a differential 
effect of different antihypertensive medication classes on BPV if one exists. 
 
The trial also has limitations that require consideration. Firstly, not all eligible patients who declined 
to participate offered a reason for their decision and this represents a missed opportunity for 
improving the trial design. Secondly, owing to the small sample size limited data regarding 
participant retention and reasons for withdrawal were obtained. Obtaining more data in both of 
these areas would have been useful for judging the feasibility of any similar future trial. Thirdly, it 
was not possible to demonstrate a differential effect on BPV between the two intervention arms. In 
part this was due to the small sample size, but it cannot be excluded that the use of antihypertensive 
agents in some participants prior to their recruitment could have influenced their BPV as recorded in 
the trial. Unfortunately, as it is accepted standard care to treat raised BP for secondary stroke 
prevention it would not be ethical to incorporate a complete washout period into the trial design. 
Therefore, follow-up in any further trials may need to be prolonged, or previous antihypertensive 
use adjusted for in the statistical analysis. 
 
In summary, CAARBS was hindered by insufficient recruitment, but did achieve its pre-specified 
feasibility objectives and demonstrate the possibility of measuring a change in BPV following an 
ischaemic stroke or TIA. With the application of modified eligibility criteria, such as retaining a longer 
window of eligibility and including patients with previous stroke, it is possible that a future trial to 
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 Lowering blood pressure variability (BPV) after ischaemic stroke may be 
beneficial. 
 This feasibility trial investigating BPV reduction did not meet recruitment 
targets. 
 Potential changes to eligibility criteria for possible future trials were identified. 
 Measuring change in BPV over a follow-up period of three months was possible. 
 Intervention to reduce BPV in the subacute phase of ischaemic stroke was safe. 
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